Skip to main content
GCTK
NASDAQ Industrial Applications And Services

Glucotrack 10-Q: Going Concern, Material Weaknesses, and Nasdaq Delisting Risk

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.367
Mkt Cap
$2.836M
52W Low
$0.25
52W High
$14.14
52W Position info
47% above low
Off High info
97% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

GCTK sits 47% above its 52-week low of $0.25 on light trading volume (0.1× avg).

Summary

Glucotrack's Q2 2026 10-Q reveals a cash crisis, going concern doubt, material weaknesses, and expanded Nasdaq delisting risk, alongside multiple dilutive financings.


Key Events · Earnings and Guidance · GCTK

  • Cash Collapse and Going Concern

    Cash fell from $7.4M to $1.1M in six months. Management states current cash won't fund the next 12 months, reaffirming substantial doubt about the company's ability to continue as a going concern.

  • Material Weaknesses Disclosed

    The company identified material weaknesses in internal controls: general IT controls, insufficient accounting personnel, and inadequate segregation of duties. Remediation is ongoing but not complete.

  • Nasdaq Delisting Risk Expands

    Beyond the existing bid price and equity deficiencies, Nasdaq's new $5M minimum market value rule (approved July 22, 2026, stayed July 29, 2026) could cause immediate delisting if it retakes effect, as the company's market value is below the threshold.

  • Dilutive Financing Cascade

    Subsequent events include a $3.5M bridge follow-on (22% OID, 8% interest, 9-month maturity), a $2M PIPE (2.67M pre-funded warrants at $0.75, common warrants at $1.50), and a $50M ELOC with White Lion Capital at 97% of VWAP or lowest traded price.


Analysis · GCTK · Industrial Applications And Services

Glucotrack's Q2 2026 report confirms the company is in severe distress. Cash has collapsed from $7.4M to $1.1M in six months, and management states current cash won't fund the next 12 months. The company also disclosed material weaknesses in internal controls for the first time, and Nasdaq delisting risk has expanded with the new $5M MVLS rule. The subsequent events section details a cascade of dilutive financings — a $3.5M bridge follow-on, a $2M PIPE, and a $50M ELOC — all at deeply discounted or variable prices. This is a survival situation, not a routine quarterly update.

At the time of this filing, GCTK was trading at $0.37 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8M. The 52-week trading range was $0.25 to $14.14. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GCTK - Latest Insights

GCTK
Aug 10, 2026, 5:32 PM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.400
Real-time Price: $0.3674 info
Change: -$0.0326 (-8%) info
Market Cap: $2.836M info
GCTK
Aug 05, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.493
Real-time Price: $0.3674 info
Change: -$0.1256 (-25%) info
Market Cap: $2.836M info
GCTK
Jul 31, 2026, 5:07 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $0.450
Real-time Price: $0.3674 info
Change: -$0.0826 (-18%) info
Market Cap: $2.836M info
GCTK
Jul 30, 2026, 5:29 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7446
Real-time Price: $0.3674 info
Change: -$0.3772 (-51%) info
Market Cap: $2.836M info
GCTK
Jul 29, 2026, 5:30 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $0.2845
Real-time Price: $0.3674 info
Change: +$0.0829 (+29%) info
Market Cap: $2.836M info